Personalising your health: an EU imperative

Area of Science:

• Biomedical Sciences
• Translational Medicine
• Healthcare Policy

Background:

• Personalised medicine offers significant potential for enhancing patient health and optimizing healthcare systems.
• The translation of novel treatments from research to clinical application (bench-to-bedside) is often hindered by various challenges.
• Current regulatory and development timelines impact the swift delivery of personalised therapies to the 500 million potential patients in the EU.

Discussion:

• Delays in the development and licensing of personalised medicine treatments are a significant barrier to patient access.
• The efficiency of healthcare systems can be improved by ensuring timely availability of tailored therapies.
• Patient-centric approaches are fundamental to the success and implementation of personalised medicine.

Key Insights:

• Slow bench-to-bedside rates impede the effective deployment of personalised medicine innovations.
• Multiple factors within the drug development and regulatory approval processes contribute to these delays.
• Optimizing these phases is essential for realizing the full potential of personalised medicine.

Outlook:

• Streamlining development and licensing pathways is critical for accelerating patient access to novel treatments.
• Future efforts should focus on patient-centric strategies to overcome existing hurdles.
• Enhanced collaboration across the healthcare ecosystem can improve the efficiency of personalised medicine delivery.